07:00 , Oct 13, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/10 cls Arrowhead Research Corp. (NASDAQ:ARWR) RBC Capital Markets Michael Yee Downgrade Sector performer (from outperform) -55% $6.37 Yee also...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Company News

Horizon Pharma, Pozen, AstraZeneca deal

Horizon will acquire U.S. rights to Vimovo naproxen/esomeprazole from AstraZeneca for $35 million in cash up front. Horizon will take over U.S. commercialization of Vimovo from AstraZeneca and ongoing U.S. patent litigation for the drug....
08:00 , Feb 18, 2013 |  BC Week In Review  |  Company News

Par Pharmaceutical, Sucampo, Takeda gastrointestinal news

Sucampo and Takeda filed suit in the U.S. District Court for the District of Delaware claiming that an ANDA from Par Pharmaceutical's Anchen Pharmaceuticals Inc. subsidiary for a generic version of Amitiza Lubiprostone infringes four...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

Budeprion XL bupropion regulatory update

Impax and Teva pulled a generic version of antidepressant Wellbutrin XL bupropion 300 mg from the market after FDA determined the generic is not bioequivalent to the branded product. FDA approved the generic in 2006...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

Shire, TWi Pharmaceuticals, Par Pharmaceutical neurology news

Shire, TWi and Par Pharmaceutical's Anchen Pharmaceuticals Inc. subsidiary settled a patent infringement suit related to an ANDA submitted by TWi for a generic version of Shire's ADHD drug Intuniv guanfacine extended release. Under the...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Clinical News

Intuniv guanfacine extended release regulatory update

Actavis Group (Zug, Switzerland) said FDA granted tentative approval of its ANDA for a generic of Shire's ADHD drug Intuniv guanfacine extended release. In 2010, Shire was notified that Actavis, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA,...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Company News

Aptalis Pharma, Teva, Mylan, Par Pharmaceutical musculoskeletal news

The U.S. Court of Appeals for the Federal Circuit (CAFC) reversed and vacated a lower court's ruling last year that two patents from Aptalis and Teva's Cephalon Inc. subsidiary covering muscle relaxant Amrix cyclobenzaprine were...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

AstraZeneca, Mylan, Osmotica Pharmaceuticals Corp., Par Pharmaceutical, Torrent neurology news

The U.S. District Court for the District of New Jersey ruled that a formulation patent covering atypical antipsychotic Seroquel XR quetiapine extended release from AstraZeneca is valid and infringed by ANDA submissions from four generics...
00:10 , Mar 31, 2012 |  BC Extra  |  Company News

Court upholds Seroquel XR formulation patent

The U.S. District Court for the District of New Jersey ruled that a formulation patent covering atypical antipsychotic Seroquel XR quetiapine extended release from AstraZeneca plc (LSE:AZN; NYSE:AZN) is valid and infringed by ANDA submissions...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

Anchen Pharmaceuticals, Par Pharmaceutical deal

Par completed its acquisition of generics company Anchen for $410 million (see BioCentury, Aug. 29). Anchen Pharmaceuticals Inc. , Irvine, Calif.   Par Pharmaceutical Cos. Inc. (NYSE:PRX), Woodcliff Lake, N.J.   Business: Generics  ...